Sona Nanotech Inc.
1 Research Drive B2Y 4M9 Dartmouth, NS, Canada

@sona_nanotech is pleased to announce the appointment of Mr. J. Mark Lievonen, C.M., to it’s Board of Directors. Mr. Lievonen is the former President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi. Mr. Lievonen is replacing Mr. Zephaniah Mbugua, who has served on the Company's Board since August 2018.... Read more: https://www.newsfilecorp.com//Sona-Nanotech-Appoints-New-D #sonavscorona #covid_19

@sona_nanotech received notice from the FDA that it’s request for an emergency use authorization (EUA) for the marketing of its rapid, COVID-19 antigen test in the United States is not a priority and consequently such authorization will not be issued at this time. The FDA cited current EUA request prioritization criteria as including the public health need for the product and did not comment on the performance of the Sona test. Health Canada continues its evaluation of ...the Company’s application for an Interim Order (IO) authorization for its test as a ‘point-of-care’ medical diagnostic device. Further, Health Canada has submitted the Company’s tests to the Public Health Agency of Canada’s National Microbiology Laboratory for evaluation, which is ongoing. Sona has already sold tests to Canadian companies under ‘research use only’ labelling. Read more: https://sonanano.com/sona-nanotech-receives-deprioritizati/

@sona_nanotech featured on @ctvatlantic This is a screening device that can be used widespread to pick up not only the virus of those people that have symptoms but importantly, before people have symptoms. At that stage, positives can be sent to the labs for confirmation but that will be result in much shorter turnaround times." - David Regan, @sona_nanotech CEO Read full story here: https://atlantic.ctvnews.ca/nova-scotia-company-waiting-on-

"Our goal is to develop a test that will provide immediate diagnosis at the scene of a possible concussion, that is both quicker and more definitive than the current subjective cognitive tests relied upon to assess for a concussion." Darren Rowles, Sona CFO Sona Nanotech Inc. announced today it has engaged Bonham/Wills & Associates, a leading sports consulting firm, to assist in securing test development sponsorship partners for its next rapid-response test project. Bonham/Wills is tasked with identifying partners to participate in the development of a prototype and eventual field validation for a test for mild-traumatic brain injury ("mTBI"), commonly referred to as concussion.

@sona_nanotech is pleased to announce that its rapid detection COVID-19 antigen test achieved a sensitivity of 84.6% and a specificity of 90.0% in a study across 99 collected clinical patient samples, which included 39 positive samples and 60 negative samples, as determined by RT-PCR testing. The Company is now continuing its submission of data to both the FDA and Health Canada to support their requirements for emergency use authorization approvals. Read more at: https://www.newsfilecorp.com//Sona-Nanotech-Announces-Clin #sonavscorona

@sona_nanotech announces that our previously announced clinical, in-field evaluation studies for our rapid detection, COVID-19 antigen test that commenced in July continue and are now expected to return their full results within two weeks. . The delays have been due to ethics review board approvals and a need to make study modifications to accommodate regulatory updates, including for study enrolment criteria and assessment at point of care settings, as well as for test handling procedures. . The data from these studies will be used to support @sona_nanotech analytical and clinical data as part of the submission it will make to Health Canada and the FDA for emergency use authorization ("EUA") approval for our COVID-19 antigen test.

@sona_nanotech has engaged Maxim Group for general financial advisory and investment banking services in relation to its planned application to list the Company’s common shares on the NASDAQ Capital Market. By up-listing to NASDAQ, the Company aspires to gain new exposure and access to a larger base of retail and institutional investors in the United States and internationally. As part of its plan to prepare for a NASDAQ listing, @sona_nanotech also announces the appointment... of David Regan as chief executive officer of the company. Full story: https://sonanano.com/sona-nanotech-engages-maxim-group-for/